Brain scans reveal how new schizophrenia drug cobenfy works

NCT ID NCT07423546

Recruiting now Knowledge-focused Sponsor: New York State Psychiatric Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 4 times

Summary

This study will use brain scans (PET/MRI) to see how the drug Cobenfy affects dopamine in the brains of 12 people with schizophrenia. Participants will take one of three doses of Cobenfy for 5 weeks and get a brain scan before and after treatment. The goal is to understand how the drug interacts with brain chemistry, not to test if it improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cobenfy (xanomeline and trospium chloride)
What this could lead to: If it works, this could help explain how Cobenfy affects brain chemistry in schizophrenia, pointing toward better treatments.
What could go wrong: This is a very small, early-phase study with only 12 people. It is designed to measure brain activity, not to test if the drug works for symptoms. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECITVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizoaffective disorder schizophrenia schizophrenia 1 schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOAFFECITVE DISORDER SCHIZOPHRENIA 1 (DISORDER)

Contacts and locations

Locations

New York State Psychiatric Institute
RECRUITING

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.